Hot Investor Mandate 2: New VC Firm Seeks Medtech, Diagnostics and Digital Health Deals in Europe

24 Nov

A new venture capital fund based in Switzerland held its first closing of approximately $30 million in 2016 and plans to have a final closing at $80 million in 2017. The firm looks to make equity investments in seed to later stage companies with initial investments ranging from around $500,000 to $3 million depending on the type and stage of company. The firm also looks to reserve additional capital for follow on financing for each investment. The firm typically looks to lead investment rounds but is also open to co-investing. The firm is currently looking for companies throughout Europe with a preference for those located in Switzerland.

The firm is looking for companies in sectors of medical devices, diagnostics, digital health, and to a lesser extent laboratory equipment. The firm is not interested in traditional biotech or pharma opportunities, only select less capital intensive drug discovery opportunities will be considered. The firm is both technology and indication agnostic, focusing more on opportunities that are not highly capital and time intensive. The firm is looking for companies that are anywhere from the prototype stage to those that have a product on the market. The firm also places significant importance on companies that can provide a clear health economic benefit to both the patients and their healthcare providers.

The firm looks for companies with driven, energetic management teams and strongly prefers companies whose management teams have (or are about to seek) complementary skills in sales, marketing, product development, as well as technical and scientific expertise. The firm is only interested in privately held companies. The firm looks to take a board seat following investment and takes a very active role in helping companies grow, leveraging both internal expertise as well as their deep external network. The firm is looking for companies that have a clear and defined business plan and is not interested in late stage research projects.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: